Dear Esteemed Friends and Investors,

We are thrilled to invite you to a virtual Private Investor Presentation on Tuesday, March 4, at 11:30 AM EST, where we’ll introduce ICaPath—a company at the forefront of transforming cancer treatment.

In this exclusive session, you will get a first-look at one of the most disruptive immunotherapy delivery platforms in the Biotech industry. ICaPath is tackling the long-standing challenges of systemic delivery and targeted therapy failures in metastatic solid tumors, with an innovation poised to transform cancer care.

Why Attend?

• ICaPath’s approach is a game-changer in the immunotherapy space, offering a novel drug-delivery platform with the potential to reverse decades of treatment failures. By attending this presentation, you’ll be among the first to learn about this revolutionary technology and its future potential.

• As we approach our Series A round, we are offering exclusive access to this early investment opportunity. Seats are limited and demand is high—don’t miss your chance to get in early on this groundbreaking biotech venture.

• ICaPath is already seeing significant momentum in the industry. The company has secured $8.5 million in funding and major institutional backing, with a lead investor committing $3 million to the Series A round. Their partnerships with top-tier clinical sites, including Johns Hopkins’ NCI-designated program, further validate the credibility and potential of this company.

• With a $70 billion market opportunity, ICaPath’s innovations aim to tackle some of the most challenging cancers—Melanoma, Soft Tissue Sarcoma, and Renal Cell Carcinoma, with plans to address pediatric cancers. Your investment doesn’t just promise financial returns—it could also transform the lives of millions of cancer patients worldwide.

Key Investment Highlights

• Revolutionary Drug Delivery Platform: ICaPath is the only company offering systemic delivery of cytokines through PLGA nanoparticles, a unique approach that enhances treatment effectiveness while reducing side effects.

• Massive Market Potential: With a total addressable market (TAM) of $70 billion, ICaPath’s solution is ideally positioned for combination therapies, further expanding its reach and efficacy.

• Unmatched IP & Licensing Potential: The company holds a global “Composition of Matter” patent for cytokines loaded in PLGA nanoparticles. ICaPath’s strategic licensing plans are poised to generate millions in non-dilutive revenues from big pharma, with additional funding for FDA trials in key oncology indications.

• Expert Leadership: The ICaPath management team brings decades of expertise in drug development, clinical trials, and licensing deals. Led by a CEO with an exceptional track record of successfully guiding biotech companies to IPO or strategic acquisition, ICaPath’s leadership is committed to delivering exceptional shareholder returns.

• Near-Term Exit Potential: ICaPath is targeting a liquidity event within 2-3 years, offering the potential for early returns through a public offering or strategic acquisition.

A Proven Track Record of Success

• Funding Commitment: With $8.5 million already invested, ICaPath is currently raising an additional $5 million in Series A funding, with a committed lead investor contributing $3 million. $2 million of this round is still available—position yourself now to join an already-oversubscribed round.

• Accelerated Path to Clinical Trials: The company has secured GMP manufacturing for its IND submissions and has partnered with Johns Hopkins for first-in-human trials, ensuring a fast track for clinical development.

Don’t miss your chance to be part of this industry-transforming opportunity.

We look forward to your participation on March 4. Secure your spot today and position yourself for the next wave of investment success!

Location

Online via Zoom

If you would like more information such as the Company’s executive summary and/or investment deck, please email Skylar Rallison at srallison@opus8.com.

We will provide a confirmation email and a calendar invitation after you register.

Thanks much and all the best,

The Opus8 Team